Glucagon-like_peptide-1_receptor

Glucagon-like peptide-1 receptor agonists and sarcopenia-related markers in diabetes: A systematic review and meta-analysis.

<p><b>AIMS</b></p><p>GLP-1 receptor agonists (GLP-1RAs) are first-line therapies for type 2 diabetes (T2DM) due to their additional weight-lowering and cardiovascular benefits. However, their impact on muscle mass is debated, posing a concern for sarcopenia in older adults with T2DM. This systematic...

๐Ÿ—“๏ธ 2025-11-05
๐Ÿ“ฐ Publication: Clinical Nutrition
Read MoreGlucagon-like peptide-1 receptor agonists and sarcopenia-related markers in diabetes: A systematic review and meta-analysis.

Muscle Mass and Glucagon-Like Peptide-1 Receptor Agonists: Adaptive or Maladaptive Response to Weight Loss?

Recent studies have shown that pharmacologic weight loss with glucagon-like peptide-1 receptor agonists (GLP-1 RAs) and combination therapies is approaching magnitudes achieved with surgery. However, as more weight loss is achieved, there is concern for potential adverse effects on muscle...

๐Ÿ—“๏ธ 2024-10-14
๐Ÿ“ฐ Publication: Circulation
Read MoreMuscle Mass and Glucagon-Like Peptide-1 Receptor Agonists: Adaptive or Maladaptive Response to Weight Loss?

Subscribe to the SCWD Newsletter

Stay Informed with the Latest Updates and Exclusive Insights!